370
Participants
Start Date
July 14, 2017
Primary Completion Date
June 7, 2022
Study Completion Date
May 9, 2025
Apixaban
Given PO
Montefiore Medical Center - Moses Campus, The Bronx
MedStar Georgetown University Hospital, Washington D.C.
UNC Lineberger Comprehensive Cancer Center, Chapel Hill
University of North Carolina, Chapel Hill
Duke University Medical Center, Durham
FirstHealth of the Carolinas-Moore Regional Hospital, Pinehurst
Cleveland Clinic-Weston, Weston
Saint Elizabeth Medical Center South, Edgewood
University of Michigan Comprehensive Cancer Center, Ann Arbor
University of Iowa/Holden Comprehensive Cancer Center, Iowa City
Froedtert and the Medical College of Wisconsin LAPS, Milwaukee
Medical College of Wisconsin, Milwaukee
Dean Hematology and Oncology Clinic, Madison
Marshfield Medical Center-Marshfield, Marshfield
Mayo Clinic Health System-Eau Claire Clinic, Eau Claire
Metro Minnesota Community Oncology Research Consortium, Saint Louis Park
Mayo Clinic in Rochester, Rochester
Altru Cancer Center, Grand Forks
NorthShore University HealthSystem-Evanston Hospital, Evanston
Northwestern University, Chicago
Illinois CancerCare-Peoria, Peoria
Carle Cancer Center, Urbana
Washington University School of Medicine, St Louis
Cancer Center of Kansas - Wichita, Wichita
University of Nebraska Medical Center, Omaha
Mayo Clinic in Arizona, Scottsdale
University of Washington Medical Center - Montlake, Seattle
Mayo Clinic in Florida, Jacksonville
Dana-Farber Cancer Institute, Boston
New Hampshire Oncology Hematology PA-Hooksett, Hooksett
Dartmouth Hitchcock Medical Center, Lebanon
Solinsky Center for Cancer Care, Manchester
National Cancer Institute (NCI)
NIH
Academic and Community Cancer Research United
OTHER